NAS10030,808+1.00%S&P7,723+0.73%GOLD$4,160−0.06%BTC$85,503+0.87%VIX15.31−6.59%live tape · as of 05:02 UTC
The Screen · Healthcare · Medical Instruments & Supplies
STAAR Surgical Company
STAA · Nasdaq · USD · Market cap $1.0B · 921 employees
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price20.32 USD
Fair value25.01
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Markup20.32+0.0% to today ✓
2026-09-13Read Markdown22.39-9.2% to today ✓
2026-08-13Read Distribution25.41-20.0% to today ✓
2026-07-02Read Accumulation28.37-28.4% to today
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
STAAR Surgical Company holds its Markdown at $20.32. The statistical read favours the sellers, held for 14 days.
As held on the ledger · 2026-09-21
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 14 days
Price at the screen
$20.32
Valuation
254.00 trailing · 19.85 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.22
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
8.49%
Below 33%
Interest-bearing debt is just 8.5% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
7.61%
Below 33%
Cash held in interest-bearing accounts and securities is 7.6% of assets, under the one-third limit.
Pass
Receivables
44.99%
Below 49%
Money owed to the company is 45.0% of assets, under the 49% limit.
Pass
Revenue purity
1.92%
Below 5%
Only 1.9% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
STAAR Surgical clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 8%, inside the ~33% line, and interest is about 2% of its income, under the ~5% line, so it passes.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-09-21 screen. The gold marker is the market price at the same screen. A 23.1% margin of safety to the base estimate.
Third-party analyst targets: 10 covering, consensus None. The average target sits +35% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Eye lens growth story still deep in the red
Picture a surgeon fitting an implantable lens that promises better sight yet the company behind it keeps losing money on every sale. STAAR Surgical shows 120% revenue growth but posts a negative 7% profit margin and negative 6% ROE at a forward multiple of 26.7 times. With our fair value sitting just below the current price we see no margin of safety and therefore pass.
The business sells phakic lenses into a specialised medical niche where analysts still carry a buy rating and a 30 dollar median target. Unknown competitive protection and ongoing cash burn outweigh that optimism. High growth in medical devices can vanish quickly once reimbursement or rival products shift.
Execution risk sits high here because losses must turn into sustainable profits before any rerating occurs. Currency moves in key export markets and regulatory hurdles add further pressure. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
STAA trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Markup · changed$20.32-9.2%Entry 6
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 9.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 61%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (9 analysts) rates it buy, with a mean price target of $30. Since the last review it its composite score rose.
2026-09-13Markdown · changed$22.39-11.9%Entry 5
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 11.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 61%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (9 analysts) rates it buy, with a mean price target of $30.
The framework has shifted from accumulation to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 10.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 61%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (9 analysts) rates it buy, with a mean price target of $30.
2026-07-18Accumulation$28.37+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 61%. Our forward projection puts the odds of a 10% gain over the next month near 27%. The street (9 analysts) rates it buy, with a mean price target of $30.
2026-07-03Accumulation$28.37+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Accumulation$28.37Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
